Gilead Sciences has issued a voluntary recall of one lot of COVID-19 antiviral Veklury, also known as remdesivir, after confirming "the presence of a glass particle" in a vial. A customer ...

Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...

Gilead Sciences has come from nowhere to dominate lists of the drugmakers with the best reputations in Asia, claiming the top spot on two-thirds of the rankings despite largely failing to make the ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Lenacapavir reduced HIV infections by 96% compared to background HIV incidence. Gilead will begin regulatory filings by the end of 2024, supporting the initial launch in 2025. Lenacapavir reduced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile, the ...

Gilead Sciences (GILD – Research Report) received a Buy rating and price target from Wells Fargo analyst Mohit Bansal today. The company’s shares closed last Friday at $84.59. According to ...